Amyris Biotechnologies Receives $24,750,000 Series C Financing

  • Feed Type
  • Date
    8/21/2009
  • Company Name
    Amyris Biotechnologies
  • Mailing Address
    5885 Hollis Street Emeryville, CA 94608
  • Company Description
    Amyris Biotechnologies is leveraging breakthroughs in synthetic biology to provide a consistent, cost-effective supply of high-value natural compounds for large and diverse markets, including pharmaceuticals, fine chemicals, nutraceuticals, vitamins, and flavors. Applying advances in molecular biology, we are engineering microbes capable of producing bioactive chemical compounds that are currently available only in limited quantities. This process, developed in the laboratory of Amyris’ founding scientist, Professor Jay Keasling at the University of California, Berkeley, gives us access to compounds unattainable by conventional chemical synthesis and eliminates the challenges associated with harvesting chemicals from natural sources.
  • Website
    http://www.amyris.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $24,750,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
    Undisclosed